These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 30242774)

  • 1. Can Arginase Inhibitors Be the Answer to Therapeutic Challenges in Alzheimer's Disease?
    Ovsepian SV; O'Leary VB
    Neurotherapeutics; 2018 Oct; 15(4):1032-1035. PubMed ID: 30242774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators.
    Panza F; Solfrizzi V; Frisardi V; Capurso C; D'Introno A; Colacicco AM; Vendemiale G; Capurso A; Imbimbo BP
    Drugs Aging; 2009; 26(7):537-55. PubMed ID: 19655822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secretase inhibitors for the treatment of Alzheimer's disease: Long road ahead.
    Kumar D; Ganeshpurkar A; Kumar D; Modi G; Gupta SK; Singh SK
    Eur J Med Chem; 2018 Mar; 148():436-452. PubMed ID: 29477076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option?
    Imbimbo BP; Panza F; Frisardi V; Solfrizzi V; D'Onofrio G; Logroscino G; Seripa D; Pilotto A
    Expert Opin Investig Drugs; 2011 Mar; 20(3):325-41. PubMed ID: 21222550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-Norvaline Reverses Cognitive Decline and Synaptic Loss in a Murine Model of Alzheimer's Disease.
    Polis B; Srikanth KD; Elliott E; Gil-Henn H; Samson AO
    Neurotherapeutics; 2018 Oct; 15(4):1036-1054. PubMed ID: 30288668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of Successful Symptomatic Treatment in Parkinson's Disease for Therapeutic Strategies of Alzheimer's Disease.
    Zhao L; Cheng X; Zhong C
    ACS Chem Neurosci; 2019 Feb; 10(2):922-930. PubMed ID: 30474958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Curr Med Chem; 2011; 18(35):5430-47. PubMed ID: 22087836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Chronic Arginase Inhibition with Norvaline on Tau Pathology and Brain Glucose Metabolism in Alzheimer's Disease Mice.
    Polis B; Squillario M; Gurevich V; Srikanth KD; Assa M; Samson AO
    Neurochem Res; 2022 May; 47(5):1255-1268. PubMed ID: 35098420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.
    Pinheiro L; Faustino C
    Curr Alzheimer Res; 2019; 16(5):418-452. PubMed ID: 30907320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arginase Inhibition Supports Survival and Differentiation of Neuronal Precursors in Adult Alzheimer's Disease Mice.
    Polis B; Srikanth KD; Gurevich V; Bloch N; Gil-Henn H; Samson AO
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32046281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of arginine-nitric oxide pathway in patients with Alzheimer disease.
    Vural H; Sirin B; Yilmaz N; Eren I; Delibas N
    Biol Trace Elem Res; 2009; 129(1-3):58-64. PubMed ID: 19099206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
    D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
    Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arginine deprivation and immune suppression in a mouse model of Alzheimer's disease.
    Kan MJ; Lee JE; Wilson JG; Everhart AL; Brown CM; Hoofnagle AN; Jansen M; Vitek MP; Gunn MD; Colton CA
    J Neurosci; 2015 Apr; 35(15):5969-82. PubMed ID: 25878270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitric oxide: target for therapeutic strategies in Alzheimer's disease.
    Fernandez AP; Pozo-Rodrigalvarez A; Serrano J; Martinez-Murillo R
    Curr Pharm Des; 2010; 16(25):2837-50. PubMed ID: 20698819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered Expression of Urea Cycle Enzymes in Amyloid-β Protein Precursor Overexpressing PC12 Cells and in Sporadic Alzheimer's Disease Brain.
    Jęśko H; Lukiw WJ; Wilkaniec A; Cieślik M; Gąssowska-Dobrowolska M; Murawska E; Hilgier W; Adamczyk A
    J Alzheimers Dis; 2018; 62(1):279-291. PubMed ID: 29439324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
    Shoaib M; Kamal MA; Rizvi SMD
    Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Norvaline Restores the BBB Integrity in a Mouse Model of Alzheimer's Disease.
    Polis B; Gurevich V; Assa M; Samson AO
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition and modulation of gamma-secretase for Alzheimer's disease.
    Wolfe MS
    Neurotherapeutics; 2008 Jul; 5(3):391-8. PubMed ID: 18625450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural insights into Entamoeba histolytica arginase and structure-based identification of novel non-amino acid based inhibitors as potential antiamoebic molecules.
    Malik A; Dalal V; Ankri S; Tomar S
    FEBS J; 2019 Oct; 286(20):4135-4155. PubMed ID: 31199070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.